Alpha Cognition Inc(ACOG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.12 | Insider Own | 8.37% | Shs Outstand | 21.8M | Perf Week | 6.88% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | 53.22% | Insider Trans | 86.14% | Shs Float | 14.2M | Perf Month | 5.28% |
| Enterprise Value | 0.16B | PEG | - | EPS next Q | -0.34 | Inst Own | 83.27% | Short Float | 2.48% | Perf Quarter | 5.04% |
| Income | -0.02B | P/S | 13.09 | EPS this Y | -12.68% | Inst Trans | 0.88% | Short Ratio | 2.86 | Perf Half Y | 56.22% |
| Sales | 0.02B | P/B | 3.77 | EPS next 5Y | - | ROA | -42.76% | Short Interest | 0.35M | Perf YTD | 41.08% |
| Book/sh | 2.43 | P/C | 4.82 | EPS past 3/5Y | 35.73% 45.28% | ROE | -55.25% | 52W High | -9.57% ($10.14) | Perf Year | 38.94% |
| Cash/sh | 1.9 | P/FCF | - | Sales past 3/5Y | - | ROIC | -44.26% | 52W Low | 103.78% ($4.50) | Perf 3Y | 18.71% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 31.08% | Gross Margin | 89.24% | Volatility(W/M) | 6.08% 5.64% | Perf 5Y | -66.65% |
| Dividend TTM | - | EV/Sales | 10.37 | Sales Y/Y TTM | 232.74% | Oper. Margin | -190.62% | ATR (14) | 0.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8 | EPS Q/Q | 38.34% | Profit Margin | -153.61% | RSI (14) | 59.09 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9 | Sales Q/Q | 267.56% | SMA20 | 4.98% ($8.73) | Beta | 2.34 | Target Price | $18 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | 2.52% ($8.94) | Rel Volume | 0.78 | Prev Close | $8.91 |
| Employees | 71 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -2.01% 36.86% | SMA200 | 28.8% ($7.12) | Avg Volume(3M) | 0.12M | Price | $9.17 |
| IPO | 2021/6/28 | Option/Short | Yes/Yes | Trades | 610 | Volume | 96,636 | Change | 2.92% |
Alpha Cognition is a pharmaceutical company developing treatments for neurodegenerative diseases, including Alzheimer's dementia and ALS (amyotrophic lateral sclerosis). Headquartered in Vancouver, Canada, the company has entered the commercialization stage after receiving U.S. Food and Drug Administration (FDA) approval for its oral tablet formulation of an Alzheimer's treatment. As a small-cap biopharmaceutical company, it is focused on expanding its neuroscience pipeline.
Over the past 1 year, on the higher side
10% below its 1-year high.
Traded less than usual. That is 78% of its average volume.
ACOG has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -12.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,309. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -66.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 83.3%.
Tap to view numbers
It ranks #301 of 594 in the industry
Based on market cap of $200M.
FAQ
What kind of company is ACOG?
ACOG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACOG?
The market cap of ACOG is approximately $200M, ranking 4,028 within its sector.
What is the 52-week high and low for ACOG?
ACOG has recorded a 52-week high of $10.14 and a low of $4.50.
